The US peptide therapeutics market is anticipated to project a CAGR of 5.0%, during the forecast period. The major factor that contributes to the country’s market growth is continuously increasing healthcare spending. According to the Peptide Therapeutics Foundation, the number of new peptides entering the clinic has been doubled in the past decade. Additionally, the four of the US-approved peptides have also achieved global sales over $1 billion. There are more than 54 therapeutic peptides that have been approved across the globe out of which the US has a considerable share of 26 drugs. Such data showcase the substantial growth of the US in the global peptide market.

Visit for Global Peptide Therapeutics Market Report at: https://www.omrglobal.com/industry-reports/peptide-therapeutics-market

The US peptide therapeutics market is segmented on the basis of route of administration and application. Based on the route of administration, the market is bifurcated into parenteral administration and oral administration. On the basis of application, the market is segmented into cancer, metabolic disorder (diabetes & obesity), gastrointestinal disorders, central nervous system disorders, respiratory disorders, and others including chronic kidney diseases, osteoporosis, and autoimmune disorder. Among these applications, the metabolic disorder dominates the market in the US. The increasing prevalence of diabetes globally created demand for insulin and hence drives the market growth.

Furthermore, some of the key players in the market include Eli Lilly & Co., Amgen Inc., Pfizer Inc., Merck & Co. Inc., Bristol Myers Squibb Co., and others. These companies are using several strategies to expand market share and gain a competitive advantage over their competitors. The strategies include new product launches, mergers and acquisitions, partnerships, and collaborations. 

For instance, in June 2019, Eli Lilly and Co. declared the US FDA approval of Emgality (galcanezumab-gnlm) injection (300 mg) for the treatment of episodic cluster headache in adults. Emgality is an innovative therapeutic approach for this neurologic disease and the first and only calcitonin gene-related peptide (CGRP) antibody approved by the FDA for two distinct headache disorders.

Research Methodology

The market study of the US peptide therapeutics market is incorporated by extensive primary and secondary research conducted by the research team at OMR. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders and industry experts. Primary research brings authenticity in our reports.

Secondary Sources Include:

• Financial reports of companies involved in the market.
• Authentic public databases 
• Whitepapers, research-papers, and news blogs.
• Company websites and their product catalogue.

The report is intended for drug manufacturing companies, pharmaceutical companies, insulin manufacturers, diabetes management companies, government organizations, regulatory bodies, hospitals & pharmacies, research institutes, and other market participants for overall market analysis and competitive analysis. The report provides in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models. 

Market Segmentation:

1. US Peptide Therapeutics Market Research and Analysis by Route of Administration
2. US Peptide Therapeutics Market Research and Analysis by Application

The Report covers:

• Comprehensive research methodology of the US peptide therapeutics market.
• This report also includes a detailed and extensive market overview with key analyst insights.
• Exhaustive analysis of macro and micro factors influencing the market guided by key recommendations.
• Analysis of regional regulations and other government policies impacting the US peptide therapeutics market.
• Insights about market determinants which are stimulating the US peptide therapeutics market.
• Detailed and extensive market segments with regional distribution of forecasted revenues.
• Extensive profiles and recent developments of market players.